^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)

    i
    Other names: KIR3DL2, Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2, CD158K, Killer Cell Immunoglobulin-Like Receptor Three Domains Long Cytoplasmic Tail, Killer Cell Immunoglobulin-Like Receptor 3DL2, P70 Natural Killer Cell Receptor Clone CL-5, Natural Killer-Associated Transcript 4, CD158 Antigen-Like Family Member K, MHC Class I NK Cell Receptor, P70 NK Receptor CL-5, NKAT-4, NKAT4, Killer Cell Immunoglobulin-Like Receptor 2DL2, Killer-Cell Immunoglobulin-Like Receptor, P70 Killer Cell Inhibitory Receptor, Killer Ig Receptor, KIR Antigen 3DL2, CD158k Antigen, KIR-3DL2, KIR3DL2, NKAT4B, Nkat4a, Nkat4b, Nkat4, 3DL2, P140, Cl-5
    3d
    KIR AA individuals possess strong inhibitory KIR alleles alongside HLA ligands that are protective against leukemia in the Chinese population. (PubMed, Front Genet)
    These data suggest that KIR AA individuals possess strong inhibitory interactions of KIR alleles and HLA, arming KIR AA + NK cells to meditate stronger alloreactivity and cytotoxicity against leukemia cells with lowered HLA expression. Our findings may provide valuable insights into leukemia pathogenesis and better understanding of the immune mechanisms.
    Journal
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • HLA-B (Major Histocompatibility Complex, Class I, B) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    2ms
    Application of a novel branched-DNA assay to quantify killer immunoglobulin-like receptor (KIR) mRNA expression identifies tissue compartmentalization in naïve and SIV-infected rhesus macaques. (PubMed, J Immunol Methods)
    Our findings reveal tissue-specific expression patterns of KIR genes that are differentially affected by chronic lentivirus infection, emphasizing the importance of compartmentalized KIR regulation in viral pathogenesis. This proof-of-concept study presents a reliable and scalable framework for the detailed characterization of the KIR gene repertoire in non-human primate models, providing a valuable alternative to traditional qPCR for profiling gene expression in complex tissues.
    Journal
    |
    CD8 (cluster of differentiation 8) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • ACACA (Acetyl-CoA Carboxylase Alpha) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    11ms
    Identifying diagnostic markers and establishing prognostic model for lung cancer based on lung cancer-derived exosomal genes. (PubMed, Cancer Biomark)
    We established a LUAD prognostic model with 12 ExoDEGs and a LUSC prognostic model with 7 ExoDEGs, which can be used as independent prognostic indicators for patients LUAD and LUSC. The identified ExoDEGs have the potential to be as prognostic markers and may also serve as novel candidate targets for the treatment of LUAD and LUSC.
    Journal
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • SLC7A5 (Solute Carrier Family 7 Member 5) • CDH17 (Cadherin 17) • FLNC (Filamin C) • SNRNP70 (Small Nuclear Ribonucleoprotein U1 Subunit 70)
    12ms
    Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). (PubMed, Front Oncol)
    The 6-GES was reduced, whereas the 17-GES was elevated at progression post axi-cel, consistent with the notion that these signatures represent features relevant for response and resistance to CAR T-cell therapy. Our transcriptomic analysis identified gene expression signatures potentially predictive of outcome with CD19-directed CAR T-cell therapy, and these findings are informative for risk stratification and development of next-generation products.
    Journal • IO biomarker
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • CD19 (CD19 Molecule) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • CCL2 (Chemokine (C-C motif) ligand 2) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • SLC16A1 (Solute Carrier Family 16 Member 1) • CCL22 (C-C Motif Chemokine Ligand 22) • SOX11 (SRY-Box Transcription Factor 11) • TNFSF4 (TNF Superfamily Member 4) • DUSP5 (Dual Specificity Phosphatase 5) • KLRB1 (Killer Cell Lectin Like Receptor B1) • NKG2D (killer cell lectin like receptor K1) • SERPINA9 (Serpin Family A Member 9) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    |
    Yescarta (axicabtagene ciloleucel)
    12ms
    KILT: Study of Lacutamab in Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=56, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    |
    gemcitabine • lacutamab (IPH4102)
    1year
    Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer. (PubMed, Front Immunol)
    The six-lncRNA pyroptosis-immune signature effectively predicted BC prognosis and highlighted distinct immune cell infiltration patterns. This holds promise for evaluating immunotherapy responses and guiding therapeutic target identification in BC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • CD40LG (CD40 ligand) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • MAPT (Microtubule Associated Protein Tau) • TDO2 (Tryptophan 2,3-Dioxygenase) • USP2-AS1 (USP2 Antisense RNA 1)
    over1year
    TELLOMAK: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, Innate Pharma | Trial completion date: Oct 2024 --> Jan 2026
    Trial completion date • Combination therapy • Metastases
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    |
    lacutamab (IPH4102)
    over1year
    KISS01: Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study (clinicaltrials.gov)
    P=N/A, N=460, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New trial
    |
    CD4 (CD4 Molecule) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • DPP4 (Dipeptidyl Peptidase 4)
    over1year
    Exploring the role of KIR3DL2 on NK cells in hepatocellular carcinoma and its potential prognostic implications. (PubMed, iScience)
    Pseudotemporal and cell communication analyses revealed these KIR3DL2high NK cells were in a quiescent state, suggesting NK cell exhaustion and poor prognosis. KIR3DL2 expression in peripheral blood NK cells correlated with that in tissues, highlighting its potential as a prognostic marker for HCC.
    Journal
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    over1year
    Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients. (PubMed, Exp Dermatol)
    Interestingly, a repeated analysis after 3 months of treatment revealed the CTCL cell death sensitivity to be restored by therapy. We propose this novel integrated approach comprising the evaluation of SC marker expression and analysis of cell death sensitivity upon treatment that can also enable a better therapy stratification.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • CD7 (CD7 Molecule) • DPP4 (Dipeptidyl Peptidase 4)
    almost2years
    IGSF8 is an innate immune checkpoint and cancer immunotherapy target. (PubMed, Cell)
    In syngeneic tumor models, anti-IGSF8 alone, or in combination with anti-PD1, inhibits tumor growth. Our results indicate that IGSF8 is an innate immune checkpoint that could be exploited as a therapeutic target.
    Journal
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    almost2years
    Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting. (PubMed, Exp Hematol Oncol)
    Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • TNFRSF8 (TNF Receptor Superfamily Member 8) • JAK1 (Janus Kinase 1) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • CDK9 (Cyclin Dependent Kinase 9) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)